tiprankstipranks
Trending News
More News >
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
US Market

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

Compare
680 Followers
See the Price Targets and Ratings of:

MIRM Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Mirum
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$69.13
▲(49.05%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $69.13 with a high forecast of $77.00 and a low forecast of $53.00. The average price target represents a 49.05% change from the last price of $46.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","78":"$78","36.75":"$36.8","50.5":"$50.5","64.25":"$64.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$77.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,36.75,50.5,64.25,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.42,46.003076923076925,48.58615384615385,51.16923076923077,53.752307692307696,56.33538461538462,58.91846153846154,61.50153846153846,64.08461538461539,66.6676923076923,69.25076923076924,71.83384615384615,74.41692307692307,{"y":77,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.42,45.39769230769231,47.37538461538462,49.35307692307693,51.33076923076923,53.308461538461536,55.286153846153844,57.26384615384615,59.24153846153846,61.21923076923076,63.19692307692307,65.17461538461538,67.15230769230769,{"y":69.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.42,44.15692307692308,44.893846153846155,45.63076923076923,46.36769230769231,47.104615384615386,47.84153846153846,48.57846153846154,49.315384615384616,50.05230769230769,50.78923076923077,51.526153846153846,52.26307692307692,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.45,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$77.00Average Price Target$69.13Lowest Price Target$53.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MIRM
TipRanks AITipRanks
Not Ranked
TipRanks
$45
Hold
-2.98%
Downside
Reiterated
05/31/25
Mirum Pharmaceuticals is showing strong revenue growth and momentum from regulatory approvals, which positively impacts its outlook. However, significant financial challenges persist due to high leverage and negative net income, affecting overall stability. The technical analysis suggests potential for upward movement, but valuation remains constrained by a negative P/E ratio. Earnings call sentiment is positive, but high operating expenses are a concern.
H.C. Wainwright Analyst forecast on MIRM
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$73
Buy
57.40%
Upside
Initiated
05/19/25
Mirum Pharmaceuticals assumed with a Buy at H.C. WainwrightMirum Pharmaceuticals assumed with a Buy at H.C. Wainwright
Raymond James Analyst forecast on MIRM
Ryan DeschnerRaymond James
Raymond James
$77
Buy
66.02%
Upside
Reiterated
05/13/25
Mirum Pharmaceuticals (MIRM) Receives a Buy from Raymond James
Citi
$68$72
Buy
55.24%
Upside
Reiterated
05/12/25
Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)
Citizens JMP Analyst forecast on MIRM
Jonathan WollebenCitizens JMP
Citizens JMP
$74$76
Buy
63.86%
Upside
Reiterated
05/09/25
Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMPMirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
Morgan Stanley Analyst forecast on MIRM
Michael UlzMorgan Stanley
Morgan Stanley
$65$70
Buy
50.93%
Upside
Reiterated
05/09/25
Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating
Evercore ISI
$68$76
Buy
63.86%
Upside
Reiterated
05/08/25
Mirum Pharamceuticals (MIRM) PT Raised to $76 at Evercore ISIEvercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $76.00 (from $68.00) while maintaining a Outperform rating.
Leerink Partners Analyst forecast on MIRM
Mani ForooharLeerink Partners
Leerink Partners
$55$56
Buy
20.74%
Upside
Reiterated
05/07/25
Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)
J.P. Morgan Analyst forecast on MIRM
Jessica FyeJ.P. Morgan
J.P. Morgan
$53
Buy
14.27%
Upside
Reiterated
04/04/25
J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MIRM
Brian SkorneyRobert W. Baird
Robert W. Baird
$50$55
Buy
18.59%
Upside
Reiterated
02/27/25
Mirum Pharmaceuticals price target raised to $55 from $50 at BairdMirum Pharmaceuticals price target raised to $55 from $50 at Baird
Stifel Nicolaus Analyst forecast on MIRM
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
$66$70
Buy
50.93%
Upside
Reiterated
11/12/24
Mirum Pharamceuticals (MIRM) PT Raised to $70 at StifelStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.
Cantor Fitzgerald Analyst forecast on MIRM
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$45$60
Buy
29.37%
Upside
Reiterated
08/07/24
Mirum Pharmaceuticals (MIRM) Receives a Buy from Cantor Fitzgerald
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MIRM
TipRanks AITipRanks
Not Ranked
TipRanks
$45
Hold
-2.98%
Downside
Reiterated
05/31/25
Mirum Pharmaceuticals is showing strong revenue growth and momentum from regulatory approvals, which positively impacts its outlook. However, significant financial challenges persist due to high leverage and negative net income, affecting overall stability. The technical analysis suggests potential for upward movement, but valuation remains constrained by a negative P/E ratio. Earnings call sentiment is positive, but high operating expenses are a concern.
H.C. Wainwright Analyst forecast on MIRM
Swayampakula RamakanthH.C. Wainwright
H.C. Wainwright
$73
Buy
57.40%
Upside
Initiated
05/19/25
Mirum Pharmaceuticals assumed with a Buy at H.C. WainwrightMirum Pharmaceuticals assumed with a Buy at H.C. Wainwright
Raymond James Analyst forecast on MIRM
Ryan DeschnerRaymond James
Raymond James
$77
Buy
66.02%
Upside
Reiterated
05/13/25
Mirum Pharmaceuticals (MIRM) Receives a Buy from Raymond James
Citi
$68$72
Buy
55.24%
Upside
Reiterated
05/12/25
Analysts Conflicted on These Healthcare Names: Regulus (NASDAQ: RGLS), Mirum Pharmaceuticals (NASDAQ: MIRM) and Kymera Therapeutics (NASDAQ: KYMR)
Citizens JMP Analyst forecast on MIRM
Jonathan WollebenCitizens JMP
Citizens JMP
$74$76
Buy
63.86%
Upside
Reiterated
05/09/25
Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMPMirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
Morgan Stanley Analyst forecast on MIRM
Michael UlzMorgan Stanley
Morgan Stanley
$65$70
Buy
50.93%
Upside
Reiterated
05/09/25
Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating
Evercore ISI
$68$76
Buy
63.86%
Upside
Reiterated
05/08/25
Mirum Pharamceuticals (MIRM) PT Raised to $76 at Evercore ISIEvercore ISI analyst Gavin Clark-Gartner raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $76.00 (from $68.00) while maintaining a Outperform rating.
Leerink Partners Analyst forecast on MIRM
Mani ForooharLeerink Partners
Leerink Partners
$55$56
Buy
20.74%
Upside
Reiterated
05/07/25
Analysts Are Bullish on Top Healthcare Stocks: Bio-Techne (TECH), Mirum Pharmaceuticals (MIRM)
J.P. Morgan Analyst forecast on MIRM
Jessica FyeJ.P. Morgan
J.P. Morgan
$53
Buy
14.27%
Upside
Reiterated
04/04/25
J.P. Morgan Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MIRM
Brian SkorneyRobert W. Baird
Robert W. Baird
$50$55
Buy
18.59%
Upside
Reiterated
02/27/25
Mirum Pharmaceuticals price target raised to $55 from $50 at BairdMirum Pharmaceuticals price target raised to $55 from $50 at Baird
Stifel Nicolaus Analyst forecast on MIRM
Dae Gon HaStifel Nicolaus
Stifel Nicolaus
$66$70
Buy
50.93%
Upside
Reiterated
11/12/24
Mirum Pharamceuticals (MIRM) PT Raised to $70 at StifelStifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.
Cantor Fitzgerald Analyst forecast on MIRM
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$45$60
Buy
29.37%
Upside
Reiterated
08/07/24
Mirum Pharmaceuticals (MIRM) Receives a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

1 Month
xxx
Success Rate
16/33 ratings generated profit
48%
Average Return
+2.64%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 48.48% of your transactions generating a profit, with an average return of +2.64% per trade.
3 Months
xxx
Success Rate
21/33 ratings generated profit
64%
Average Return
+7.19%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +7.19% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
15/16 ratings generated profit
94%
Average Return
+31.31%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +31.31% per trade.
2 Years
xxx
Success Rate
34/36 ratings generated profit
94%
Average Return
+54.90%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +54.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
5
4
4
4
8
Buy
8
10
11
9
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
14
15
13
11
In the current month, MIRM has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 69.13.
Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$0.33 with a range of -$0.50 to -$0.21. The previous quarter’s EPS was -$0.30. MIRM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.
Next quarter’s earnings estimate for MIRM is -$0.33 with a range of -$0.50 to -$0.21. The previous quarter’s EPS was -$0.30. MIRM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $107.36M with a range of $103.44M to $110.60M. The previous quarter’s sales results were $111.58M. MIRM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.
Next quarter’s sales forecast for MIRM is $107.36M with a range of $103.44M to $110.60M. The previous quarter’s sales results were $111.58M. MIRM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year MIRM has Outperformed its overall industry.

MIRM Stock Forecast FAQ

What is MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals Inc’s 12-month average price target is 69.13.
    What is MIRM’s upside potential, based on the analysts’ average price target?
    Mirum Pharmaceuticals Inc has 49.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MIRM a Buy, Sell or Hold?
          Mirum Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mirum Pharmaceuticals Inc’s price target?
            The average price target for Mirum Pharmaceuticals Inc is 69.13. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $77.00 ,the lowest forecast is $53.00. The average price target represents 49.05% Increase from the current price of $46.38.
              What do analysts say about Mirum Pharmaceuticals Inc?
              Mirum Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of MIRM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis